Day: December 26, 2022

Appointment Part of Apollo’s Continued Buildout in Japan and Long-term Commitment to Providing Fixed Income Replacement and Alternative Investment Solutions for the Japanese Market NEW YORK, Dec. 26, 2022 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Tatsuo Tanaka has been named as Japan Chair to Apollo. Mr. Tanaka is a 50-year veteran of the banking and finance industry in Japan, having held various senior positions in leading financial institutions, including as Deputy President of MUFG Bank and Mitsubishi UFJ Financial Group, Chairman of Union Bank and, most recently, Chairman of Citigroup Japan. Mr. Tanaka’s appointment reflects Apollo’s continued growth in its asset management and retirement services businesses in Japan.   “This new role is a reflection of the importance we place on Japan and the growth opportunities...

Amsterdam, Netherlands, 26 December 2022 19:30 CET: Following the announcement made on 21 December 2022 related to the Court order granting the Company permission to convene the Scheme Meeting, VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, and its subsidiary, VEON Holdings B.V. (the “Company”) hereby give notice that the OFAC License referred to in the previous announcement has been granted, such that the Company is satisfied that it has obtained all necessary OFAC related Authorisations for the Scheme. The OFAC License authorises all noteholders (and their funds, fund managers, investment advisors or subadvisors), financial institutions, clearing and trading systems, trustees, paying and security agents, registrars, and other service providers, intermediaries,...

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, for toripalimab in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma is granted an exclusive license to develop and commercialize toripalimab injection in all its MENA markets. In addition, Junshi Biosciences will grant the right of first negotiation to Hikma for the future commercialization of three under development drugs in MENA. Toripalimab is an innovative anti-PD-1 monoclonal...